Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 12;7(1):35.
doi: 10.1038/s41531-021-00179-6.

Synucleinopathy-associated pathogenesis in Parkinson's disease and the potential for brain-derived neurotrophic factor

Affiliations
Review

Synucleinopathy-associated pathogenesis in Parkinson's disease and the potential for brain-derived neurotrophic factor

Kathryn M Miller et al. NPJ Parkinsons Dis. .

Abstract

The lack of disease-modifying treatments for Parkinson's disease (PD) is in part due to an incomplete understanding of the disease's etiology. Alpha-synuclein (α-syn) has become a point of focus in PD due to its connection to both familial and idiopathic cases-specifically its localization to Lewy bodies (LBs), a pathological hallmark of PD. Within this review, we will present a comprehensive overview of the data linking synuclein-associated Lewy pathology with intracellular dysfunction. We first present the alterations in neuronal proteins and transcriptome associated with LBs in postmortem human PD tissue. We next compare these findings to those associated with LB-like inclusions initiated by in vitro exposure to α-syn preformed fibrils (PFFs) and highlight the profound and relatively unique reduction of brain-derived neurotrophic factor (BDNF) in this model. Finally, we discuss the multitude of ways in which BDNF offers the potential to exert disease-modifying effects on the basal ganglia. What remains unknown is the potential for BDNF to mitigate inclusion-associated dysfunction within the context of synucleinopathy. Collectively, this review reiterates the merit of using the PFF model as a tool to understand the physiological changes associated with LBs, while highlighting the neuroprotective potential of harnessing endogenous BDNF.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Pathogenic mechanisms consistently associated with Lewy bodies across multiple approaches.
Both immunofluorescence and LCM of LB-containing nigral neurons reveal alterations in proteolysis markers, as well as alterations in transport/cytoskeleton organization,. Some whole SN tissue analysis and LCM studies of nigral DA neurons also have detected proteolysis and transport/cytoskeletal dysfunction–,,. Mitochondrial dysfunction is quite frequently detected by both whole SN tissue analysis and LCM approaches–,,, however the association specifically with LBs has not directly been established.

References

    1. Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front Neurol. 2018;9:156. doi: 10.3389/fneur.2018.00156. - DOI - PMC - PubMed
    1. Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev. Neurol. (Paris) 2018;174:628–643. doi: 10.1016/j.neurol.2018.08.004. - DOI - PubMed
    1. Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha synuclein to neuronal survival and function—implications for Parkinson’s disease. J. Neurochem. 2016;137:331–359. doi: 10.1111/jnc.13570. - DOI - PMC - PubMed
    1. Obeso JA, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Mov. Disord. 2017;32:1264–1310. doi: 10.1002/mds.27115. - DOI - PMC - PubMed
    1. Iwai A, et al. The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467–475. doi: 10.1016/0896-6273(95)90302-X. - DOI - PubMed

LinkOut - more resources